

Asthma Therapeutics Industry Report: Competitive Landscape and Future Prospects

*The Business Research Company's
Asthma Therapeutics Industry Report:
Competitive Landscape and Future
Prospects*

LONDON, GREATER LONDON, UNITED
KINGDOM, August 20, 2025

/EINPresswire.com/ -- "Get 30% Off All
Global Market Reports With Code

ONLINE30 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors



The Business
Research Company

The Business Research Company

What Is The Projected Market Size & Growth Rate Of The Asthma Therapeutics Market?

In recent times, the size of the asthma therapeutics market has seen robust growth. From \$30.63 billion in 2024, it's projected to increase to \$33.11 billion by 2025, with a compound annual growth rate (CAGR) of 8.1%. This significant growth during the historical period is primarily due to factors such as heightened awareness of asthma management, the increasing use of inhalers and nebulizers, a higher incidence of allergic asthma attributed to pollution, increased government efforts to promote respiratory health, and the expansion of healthcare infrastructures in emerging economies.

“

It will grow to \$44.53 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%.”

*The Business Research
Company*

In the coming years, the asthma therapeutics market is predicted to experience significant expansion. The market is projected to swell to a value of \$44.53 billion by 2029, with a compound annual growth rate (CAGR) of 7.7%. Factors anticipated to propel growth in this forecast period include the heightened demand for biologics in combating asthma, the broader emphasis on personalized medicine, the proliferation of digital inhalers and intelligent healthcare devices, a surge in cases of pediatric asthma, and an upswing in investment for the research and development of innovative therapeutics. Some of the key trends predicted for the forecast period involve advancements in biologic treatments for severe asthma, the evolution of inhaler technologies incorporating digital tracking, the creation of personalized treatment strategies for asthma, breakthroughs in drug-delivery systems, and the incorporation of artificial intelligence and wearable tech in the monitoring of asthma.

Download a free sample of the asthma therapeutics market report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=25702&type=smp>

What Is The Crucial Factor Driving The Global Asthma Therapeutics Market?

The escalation in the frequency of asthma is anticipated to stimulate the expansion of the asthma therapeutics market. Asthma is a chronic disease characterized by inflammation and swelling of the airways, which causes narrowing of the passages conveying air from the nose and mouth to the lungs. The amplified occurrence of asthma can be attributed to rising levels of pollutants that irritate the airways and increase susceptibility to the condition. Asthma therapeutics play a crucial role in managing asthma by helping control inflammation of the airways, alleviating symptoms, and preventing asthma attacks. Long-term control drugs like inhaled corticosteroids are essential for reducing chronic inflammation, and quick-relief medications such as bronchodilators offer immediate relief during flare-ups. For illustration, in April 2024, Asthma + Lung UK, a charity in England that supports individuals with lung conditions, suggested that the fatalities attributed to asthma in England increased from 1,146 in 2021 to 1,236 in 2022. Therefore, the surging incidences of asthma are fueling the development of the asthma therapeutics market.

Who Are The Emerging Players In The Asthma Therapeutics Market?

Major players in the Asthma Therapeutics Global Market Report 2025 include:

- Roche Holding AG
- Merck & Co Inc.
- Pfizer Inc.
- AstraZeneca plc
- Sanofi S.A.
- Novartis AG
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
- Boehringer Ingelheim GmbH

What Are The Key Trends Shaping The Asthma Therapeutics Industry?

Key players in the asthma therapeutics market are concentrating their efforts on creating novel products, like fixed-dose combination (FDC) medications, with the aim of boosting the effectiveness of treatment and increasing patient compliance. A fixed-dose combination (FDC) drug amalgamates two or more active pharmaceutical components in a single mode of administration, such as a tablet or inhaler, to address a specific ailment. For example, Glenmark Pharmaceuticals Limited, a pharma firm based in India, unveiled an innovative fixed-dose combination (FDC) drug, Indacaterol plus Mometasone, for the treatment of asthma in June 2022. Indacaterol, a long-acting beta-agonist (LABA), functions by relaxing airway muscles while Mometasone, an inhaled corticosteroid (ICS), mitigates lung inflammation. With this FDC,

improved symptom management and the convenience of daily dosing are aimed to be provided, thus encouraging treatment adherence among patients with moderate to severe asthma.

What Segments Are Covered In The Asthma Therapeutics Market Report?

The asthma therapeutics market covered in this report is segmented –

- 1) By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Short-Acting Beta Agonists (SABA), Biologics, Combination Inhalers (ICS + LABA)
- 2) By Treatment Stage: Acute Treatment, Long-Term Control, Preventive Treatment, Maintenance Regimens, Rescue Medications
- 3) By Route Of administration: Oral, Inhaled, Intravenous, Subcutaneous
- 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- 5) By End-User: Hospitals, Homecare, Specialty Clinics

Subsegments:

- 1) By Inhaled Corticosteroids (ICS): Fluticasone, Budesonide, Beclomethasone, Mometasone, Ciclesonide
- 2) By Long-Acting Beta Agonists (LABA): Salmeterol, Formoterol, Indacaterol, Olodaterol
- 3) By Leukotriene Receptor Antagonists (LTRA): Montelukast, Zafirlukast, Pranlukast
- 4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol), Levalbuterol, Terbutaline
- 5) By Biologics: Omalizumab, Mepolizumab, Benralizumab, Dupilumab, Reslizumab
- 6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol, Budesonide + Formoterol, Mometasone + Indacaterol, Beclomethasone + Formoterol

View the full asthma therapeutics market report:

<https://www.thebusinessresearchcompany.com/report/asthma-therapeutics-global-market-report>

Which Region Is Projected To Hold The Largest Market Share In The Global Asthma Therapeutics Market?

In 2024, North America led the global asthma therapeutics market. It is anticipated that the Asia-Pacific region will experience the most rapid growth during the forecast period. The regions analyzed in the asthma therapeutics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Reports Similar to the Global Asthma Therapeutics Market 2025, By [The Business Research Company](#)

Asthma Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report>

Anti Asthmatics And Copd Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market>

Asthma Spacers Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/asthma-spacers-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/841434779>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.